Tag: NASDAQ
Fair Prospects ahead for Sirona Biochem with Grant of Key Patent...
Sirona Biochem (OTCPK: SRBCF), a biopharmaceutical company focused on discovering novel cosmetic and pharmaceutical compounds, announced the grant of a patent for TFC-1067, its...
Gene Therapy offers Cure for Bubble Boy Syndrome
Severe combined immunodeficiency (SCID) or “Bubble Boy Syndrome” is a rare genetic disorder caused by gene mutations that inhibit the functioning of immune cells....
ReWalk Raises $5M for its ReStore Exosuit for Stroke Victims
Standing Tall
ReWalk Robotics (NASDAQ: RWLK) recently received an approval for its ReStore exoskeleton system, indicated for rehabilitation of stroke victims, from the FDA. The company...
The Emerging Paradigm in HIV Therapeutics Offers Hope for a Cure
Human Immunodeficiency Virus (HIV) compromises the body’s immunity by attacking CD4 cells (a type of T cell), exposing it to a host of infections...
Obalon Granted First US Patent for its Proprietary Intragastric Balloon System.
Obalon Therapeutics (NASDAQ: OBLN), the manufacturer of the first and only FDA-approved swallowable, gas-filled intragastric balloon system to combat obesity, has announced the grant...
Share Skyrockets on news of positive early-stage results from GEN-009 Clinical...
Genocea Biosciences, Inc. (NASDAQ: GNCA) skyrocketed today based on news of promising data from its early stage clinical trials of GEN-009, its neoantigen vaccine candidate....
Research in Biologics and Small Molecules aim to unravels the genetics...
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes the body’s immune system to attack healthy tissue causing inflammation, photosensitivity, oral ulcers, pleuritis,...
Can Cara Therapeutics buck the trend?
Cara Therapeutics (NASDAQ: CARA) recently posted its first quarter, 2019 results. The company reported a net loss of $22.0 million, or $0.56 per basic...
Emerging Treatment Paradigms in Focal Segmental Glomerulosclerosis (FSGS)
Focal segmental glomerulosclerosis (FSGS) is a disease caused by the degeneration of glomeruli, the filtering system of the kidney’s and is caused by factors...
G1 Therapeutics stock soars on news of NDA for Triaciclib
G1 Therapeutics (NASDAQ: GTHX) shares soared by almost 25% on the basis of news that it had a productive phase 2 meeting with the...
We are looking for talented interns to learn and help investors find valuable companies.